Through tumor profiling, TPC creates breakthrough advances in disease understanding to improve the standard of care for cancer patients.
Leading experts at ETH Zurich, University of Zurich and University Hospital Basel are working together to develop groundbreaking insights into cancer biology. These insights improve disease understanding and the standard of care for patients.
From tumor profiling to better treatment strategy decisions – how does it work?
First, a patient's tumor material is analysed using the TPC tumor profiling technologies.
The resulting data are then combined with clinical diagnostic results and clinical data to generate a molecular research report for each patient.
Next, this report is discussed in a pre-tumor board, where a multidisciplinary group of physicians makes treatment recommendations. These recommendations, based on (i) ESMO clinical guidelines, (ii) new clinical diagnostic procedures and (iii) data generated by the TPC technologies, along with a summary of the pre-tumor board discussion, are sent to the tumor board. This interdisciplinary expert panel makes the final decision on the best treatment strategy, taking into account all available information about the individual patient.